Clinical and therapeutic outcomes of COVID-19 intensive care units (ICU) patients: a retrospective study in Ghana
Jane Afriyie-Mensah1,2, Elvis Twumasi Aboagye3, Vincent Jessey Ganu2, Samuel Bondzi2, Dennis Tetteh2, Ernest Kwarteng1, Joseph Akamah1,2, Alfred Doku1,2, Patrick Adjei1,2,&
1Department of Medicine and Therapeutics, College of Health Sciences, University of Ghana Medical School, University of Ghana, Accra, Ghana, 2Department of Medicine, Korle-Bu Teaching Hospital, Accra, Ghana, 3West African Centre for Cell Biology of Infectious Pathogens, Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana
Patrick Adjei, Department of Medicine and Therapeutics, College of Health Sciences, University of Ghana Medical School, University of Ghana, Accra, Ghana
The COVID-19 pandemic had caused significant morbidity and mortality, with over a million deaths recorded to date. Mortality recorded among severe-critically ill patients admitted to intensive care units (ICU) has been significantly high, especially in most COVID-19 epicenters. Reports on the unique clinical characteristics and outcomes from the ICU admissions are on-going with isolated studies in Africa. This study was a retrospective single-centre study involving all polymerase chain reaction (PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients admitted to the medical intensive care unit (MICU) of the department of medicine and therapeutics, Korle-Bu Teaching Hospital, over the period of 13th April - 28th June 2020. Twenty-two (22) patients in total fulfilled the inclusion criteria and are included in this report. Patients' socio-demographic characteristics, clinical and laboratory parameters outcomes as well as treatment modalities employed were extracted from their respective medical records and analyzed using STATA version 14. Dyspnoea, fever and cough were most common associated symptoms. The mean duration of admission at the ICU was 4.1 ± 3.0 days with five deaths (22.7%). About 91% (20/22) had at least one comorbidity with hypertension as the most prevalent. The median oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) level was significantly higher in persons with only COVID-19 pneumonia compared to those with complicated respiratory failure (p<0.001). Six (27.3%) out of the 22 patients had non-invasive ventilation, with only 1/22 (4.5%) receiving mechanical ventilation. Although non-significant, the mean duration of ICU stay was relatively shorter in patients who received therapeutic doses of anticoagulation (p=0.32). Duration of treatment with methylprednisolone was significantly associated with patient outcomes (p=0.04) and serum ferritin levels had a tendency to negatively affect outcome (p=0.06). Clearly there are still no specific targeted medications for COVID-19 treatment, except for empirically symptoms-guided treatments and management of mild to critically ill patients. Early use of systemic corticosteroids for severe to critically ill patients in the ICU using S/F ratio and CRP levels may improve outcomes.
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has fast evolved into a pandemic with unimaginable impacts on healthcare systems globally . The onset of this pandemic since 29th December 2019 has stretched the health systems of many countries particularly the already limited intensive care space which is immensely required to care for those with the severe and critical forms of the disease . There are significant morbidity and mortality resulting from the pandemic, with over a million deaths recorded to date . Although SARS-CoV-2 incidence and rate of transmission in some parts of Europe, Asia and America are yet to be stabilize, Africa among other nations experienced a relatively low incidence and mortality . The clinical manifestations of COVID-19 resulting from SARS-CoV-2 infection, vary widely in severity, ranging from mild to moderate symptoms in about 80% , to severe-critical disease with rapid progression in about 20% of affected individuals, with a high case fatality in the latter group . Early in the pandemic, it became clear that older age (60 years and above), male sex and the presence of underlying medical conditions such as cardiovascular disease, diabetes, chronic respiratory disease and cancer are major risk factors for developing severe to critical illness with an increased tendency of ICU admission and mortality [5,6]. However, these identified risk factors do not completely explain why some affected individuals experience none or mild/moderate symptoms while others become severely ill.
Severe COVID-19 is characterized by dyspnea (RR>30bpm), hypoxia with SpO2<93% on RA or >50% lung involvement on chest imaging and the presence of respiratory failure defined as partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) <300 or SpO2/FiO2 <315, shock or multi-organ dysfunction defines critical illness . Although acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) appears to be the major cause of death, severe COVID-19 has also been linked with cardiovascular sequelae, such as myocardial injury, arrhythmias, cardiomyopathy and heart failure, acute kidney injury often requiring renal replacement therapy, neurological complications, encephalopathy and acute ischemic stroke . Recent evidence has revealed that COVID-19 induced coagulopathy occurs presenting as micro- and macro-vascular thrombosis in both venous and arterial vasculature . These complications account for the high mortality among patients admitted to the ICU with a variable case fatality of between 30-67%, particularly among mechanically ventilated patients [10-13]. Management strategies used in supporting ICU patients keeps evolving with the aim of optimizing care and reducing mortality. Reports on the clinical characteristics of severe to critically ill COVID-19 patients admitted to the ICU have largely been from outside Africa. With the current trend of a likely second wave of SARS-CoV-2 resurgence in Europe (for example France and England among many others) we reviewed the clinical characteristics and treatment outcomes of patients admitted to the MICU of the Korle-Bu Teaching Hospital in Ghana. Results of this review may impact both local and national clinical treatment guidelines to advance COVID-19 care.
Ethical approval: the study was conducted according to the ethical guidelines of the declaration of Helsinki. The Scientific and Technical Committee (STC) and the Institutional Review Board (IRB) of the Korle-Bu Teaching Hospital approved this study (KBTH STC/IRB 000111/2020).
Study design, site and participants: this was a retrospective single-centre review of patients with laboratory confirmed diagnosis of SARS-CoV-2 infection, admitted to the medical intensive care unit (MICU) of the department of Medicine, Korle-Bu Teaching Hospital from 13th April to 28th June 2020. The MICU had since April 2020, been dedicated for the admission of COVID-19 patients presenting to the hospital with severe to critical disease. Laboratory confirmation of SARS-CoV-2 infection were conducted with the 2019-nCoV real time-polymerase chain reaction (RT-PCR) at the Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra, using nasopharyngeal swabs.
Data collection: a chart review of the clinical records of the patients were conducted. Data extraction form were used to obtain patients´ characteristics with parameters that includes patients´ socio-demographic variables, clinical characteristics and laboratory parameters. The socio-demographic characteristics extracted included age, sex and occupation. Data on clinical characteristics extracted included clinical history, co-morbidities present, signs and symptoms at admission including SpO2/FiO2 (S/F) ratio, duration on admission, initial laboratory parameters including inflammatory markers; D-dimer levels, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, lactate dehydrogenase (LDH) and interleukin 6 (IL-6), medications administered, complications developed during admission and clinical outcomes (discharge from MICU or death). The data extracted were reviewed by two independent research investigators as part of data validation and quality checks.
Data definitions a) the criteria for admission to the MICU was PCR positive SARS-CoV infection associated with: severe disease defined as having oxygen saturation (SpO2) less than or equal to 93% on room air with increasing oxygen demands, respiratory rate (RR) >30 bpm, >50% lung involvement on chest imaging and S/F ratio <315; critical disease characterized by organ/multi-organ dysfunction (lung plus any other) and evidence of sepsis/septic shock (using Q-sofa criteria). Raised serum inflammatory markers such as CRP, ESR, IL-6 and ferritin levels was used as a determinant of a systematic inflammatory response; b) cardiac Injury was defined by elevated troponin I levels (>0.16ng/ml); c) acute kidney Injury (AKI) was defined as abnormal urea and creatinine in a non-chronic kidney disease (CKD) patient; d) hepatic injury was defined as having deranged liver enzymes.
For the pruposes of the study and in the absence of arterial blood gases (ABGs) for objective definition of ARDS, all patients with S/F ratio <311 were defined as having acute respiratory distress syndrome (ARDS) as described earlier by Bashar F et al. 2018 .
Standard MICU treatment protocol: MICU patients with abnormal S/F ratio (<400) ± elevated inflammatory markers (particularly CRP >70mg/L) were started on high dose IV methylprednisolone (100mg) stat and infusion of 400mg over 24 hours for day 1, subsequently given 250mg infusion daily for 5 days and/or till S/F >400: all patients with myocardial involvement also received IV methylprednisolone; all patients received Tab doxycycline 200mg stat and 100mg twice daily for 10day, vitamin C 1000mg daily and zinc tablets 60mg daily; intravenous (IV) antibiotics were administered to severely ill patients with fever and neutrophilia; all patients received prophylactic SC clexane of 40mg daily except for those with D-dimer levels ≥5ug/ml who received therapeutic doses at 1mg/kg; in the absence of highflow oxygen, supplementary oxygen was titrated to obtain SpO2 target of at least 94% using nasal prong, simple facemasks or non-rebreather masks. Patients who couldn´t achieve target SpO2 on 15L non-rebreather were put on noninvasive ventilation (CPAP) and patients with deteriorating saturations despite non-invasive ventilation were candidates for mechanical intubation.
Statistical analysis: the data was entered into an excel sheet and exported into STATA version 14 for all analysis. Categorical data were analyzed and presented as frequencies and percentages and compared for any significant difference using chi square or Fischer´s exact test accordingly. The Chi-square test was used to compare clinical symptoms to clinical outcomes and also to compare the effect of having a comorbidities on the clinical outcome. Continuous variables were analyzed and presented as median and interquartile ranges and means with standard deviations where appropriate. P-values less than 0.05 were considered statistically significant.
Demographic and clinical characteristics: a total of 22 patients were admitted to the MICU over the period with 12 (54.5%) of the patients directly admitted from other referral centers and the rest from within the hospitals´ COVID-19 treatment centre. The median age of the MICU patients was 62 years (age range of 17-81 years) with 63.6% (14/22) being at least 60 years. About 55% of patients were males. The most prevalent symptoms were dyspnoea, fever and cough (Table 1). The median SpO2/FiO2 ratio of admitted patients were 373.8 with an interquartile range of 204.2 - 433.3. Ten patients (45.5%) had S/F ratio <315 and 5 (22.7%) of patients died (Table 1). At time of analysis, one patient was still on admission with 16 (72.7%) successfully discharged from ICU.
Comorbidities and duration of ICU stay: twenty (90.9%) of the MICU patients had at least one comorbidity with hypertension being the most prevalent followed by diabetes 13 (59.1%) (Table 2). Two patients (9.1%) were newly diagnosed with HIV and only one patient was on chemotherapy for multiple myeloma. The mean duration of ICU stay was 4.1 ± 3.0 days with a range of 1 to 7 days.
Complications developed: approximately 91% (20/22) of the patients had COVID-19 related respiratory pneumonia with 54.5% having >50% lung involvement on chest CT-scans. Half (10/20) of those with COVID-19 pneumonia had ARDS using S/F ratio threshold of <311 (Table 3). The S/F ratio was significantly lower in patients with uncomplicated COVID-19 pneumonia when compared to those with ARDS (Figure 1). Nine (40.9%) had neurological complications in the form of confusion, hallucination, altered sensorium and anosmia. Cardiovascular complications such as arrythmias and strokes occurred in 2 (9.1%) and 2 (9.1%) respectively and 1 patient (4.5%) had sepsis. Acute kidney Injury (AKI) occurred in 8 patients (36.4%) and acute lower gastrointestinal bleeding occurred in 2 cases (9.1%).
Laboratory characteristics: the median values of haemoglobin (Hb), platelets, WBC including differential cell counts were normal (Table 4). The median values of inflammatory markers such as serum ferritin, CRP, LDH and ESR were all elevated above the normal range (Table 4). C-reactive protein levels >70 was noted in 13/19 (68.4%). D-dimer levels were elevated in 19/22 patients (86.4%) with a median value of 5.0 and that of troponin T was 0.2 (Table 4). Evidence of transaminitis and cholestasis occurred in about 6/19 (32.6%) and abnormal blood urea and creatinine in 8/22 (36.4%) of the patients (Table 4).
Treatment and outcomes: six (27.3%) had non-invasive ventilation (CPAP) and only 1/22 (4.5%) was mechanically ventilated (Table 5). All patients received anticoagulation with 8/22 (36.4%) having received therapeutic doses and the rest prophylactic doses. Approximately 73% (16/22) were given IV methylprednisolone and the mean duration of therapy was 4.9 ± 2.3 days (Table 5). For the methylprednisolone group, the mean duration of therapy was significantly shorter among non-surviving patients compared to surviving patients (p=0.04; Table 6). There was a tendency to have poor outcome with lower S/F ratio, higher serum ferritin and a higher FiO2 requirement although not statistically significant (p=0.07; 0.06; 0.06) respectively (Table 6). All-cause mortality rate among the ICU patients was 22.7% (5/22) (Table 1). Two (40%) of the deaths were due to acute respiratory failure whiles sepsis, acute strokes, acute lower GI bleed with hemodynamic compromise and fatal arrythmia (ventricular fibrillation) accounted for the other three deaths. There was no significant association between the number of complications one had and the clinical outcome (χ2=3.82 p=0.148).
This retrospective review of clinical and therapeutic an outcome of severe COVID-19 cases admitted to the ICU is timely and in line with health care system measures and preparations for the emerging second wave of the pandemic. A review suggested that the ICU mortality rate for COVID-19 patients witnessed a drop to about one-third in mid-2020 compared to the start of the pandemic, partly due to the improved hospital care and symptomatic management of the disease . However, some limitation exists in the understanding of the full clinical course of the disease among the severe to critically ill and more clarity will help reduce mortality significantly especially among ICU patients. This study to the best of our knowledge is among the first observational study that has reviewed clinical outcomes of COVID-19 patients admitted to ICU in sub-Saharan Africa.
Demographic characteristics and associated comorbidities: the current report replicates the finding of advanced age as a significant risk factor for developing severe to critical COVID-19 and for ICU admission [5,6,11]. The MICU patients reviewed had a median age of 62 years, with more than 64% being above 60 years. In a US study by Gold et al. ICU admission significantly increased with age as 53.8% of all hospitalized patients above 65 years were admitted to the ICU . The older age risk has been linked to the increased chance of the aged having more comorbidities compared to the younger population, hence the observed poor disease outcome. It is also thought that the medications used to manage the existing comorbidities may compromise the immune system culminating in the severe disease pattern. Other responsible factors considered include slower response to viral alerts by aging of immune cells (immune senescence) allowing for high orders of viral replications. In addition, as one ages, the thymus responsible for pumping out T-cells shrinks in size, decreasing the number of T-cells release, affecting many aspects of the general immune response action .
Although the study was limited by the small sample size to make any conclusions on male to female ratios, the slight male predominance (55%) observed in the current report confirms earlier suggestions of higher infection rate in men compared to women. It was thought to be too early when the gender gap emerged initially in infection rates globally. However, subsequent studies have pointed to possible factors like higher expression of angiotensin-converting enzyme-2 receptors for COVID-19 virus in males than females, as well as the sex based immunological differences . A large aspect of the gender difference has been associated with lifestyle, like higher levels of smoking and drinking in men more than women. There are also the opinion that generally, women showed responsible attitude toward coronavirus during the epic period than men´s reluctance in taking the preventive measures .
Presence of comorbidities has been associated with disease severity, ICU admission and poor outcomes. Similarly, about 90% of all MICU patients had associated comorbidities, mainly hypertension and diabetes which have been shown to be the most common comorbidities with poor prognosis [5,6,12]. What remains to be clarified is whether the association is statistically significant or merely a confounder, since the two conditions are common medical conditions in the elderly. Other notable but less prevalent comorbidities among the MICU patients included multiple myeloma on chemotherapy, sickle cell disease and HIV which are linked with immune status suppression.
Complications developed: COVID-19 infection has been shown to be associated with a heightened systemic inflammatory response in a sub-group of patients who develop severe disease and is characterized by the increased release of chemokines and cytokines such as interleukins and interferons into the blood stream called the “cytokine storm” . The uncontrolled release of these inflammatory mediators fuels an abnormal systemic inflammatory response similar to what occurs in other viral infections (coronaviruses and influenza). This phenomenon is life threatening as it plays a key role in the development of complications such as ARDS and multi-organ failure. Majority (91%) of MICU cases had COVID pneumonia (confirmed on HRCT with >50% lung involvement in 60% of the patients), which emphasizes that COVID-19 primarily affects the respiratory system. This explains the lower mean S/F ratio observed among the MICU patients and the predominance of dyspnea and cough as a presenting symptom in >90% of them. The Berlin criteria defines ARDS using the physiological P/F ratio of ≤300 which significantly correlates with an S/F ratio value of 311 from a large cohort study by Bashar et al. . Using this cut off S/F ratio, 50% (10/20) of the MICU patients with covid pneumonia had ARDS whiles the rest had uncomplicated COVID pneumonia. This proportion was lower compared to a similar study by Arentz et al. in which 71% of their ICU patients developed ARDS but Wu et al. reported a lower prevalence of ARDS being 41.8% [11-20]. It has been shown that COVID-19 related diffuse alveolar damage (DAD) presenting as acute lung injury (ALI)/ARDS appear to be the major cause of ICU admissions and mortality [11,12].
Organ dysfunction aside the lungs have been associated with severe acute respiratory viral diseases, similarly observed in COVID-19 patients with variable reported prevalence . A study by Cui X et al. reported an AKI prevalence of 18.1% in COVID-19 patients with an increased risk in those with severe disease . This was lower compared to the prevalence of 29% reported by Yang et al. among ICU patients with severe to critical disease . The prevalence of AKI among the MICU patients was higher (36.4%) but none required dialysis. Approximately 30% of the ICU patients had evidence of liver injury with elevated transaminases and intra-hepatic cholestasis either alone or in combination. A study by Huang et al. reported a higher prevalence (62%) of liver dysfunction among ICU patients with severe COVID-19 disease compared to 25% in non-ICU patients .
Neurological complications in the form of confusion, anosmia, hallucination and altered sensorium have also been noted with varied prevalence in patients with COVID-19 [23,24]. Although Helms et al. reported a higher prevalence of 84% among severely ill patients, our review showed a prevalence of 40.9% having anosmia, hallucination, confusion and altered sensorium . Cardiac complications in the form of arrhythmia occurred in 2 (9.1%) of the MICU patients which was lower compared to arrythmia prevalence of 16.7% in a cohort of chinese patients with COVID-19 . The pathophysiology of cardiac complications in COVID-19 are numerous including the increased presence of cytokines and chemokines in the blood and its effect on the myocardium, hypoxia related myocardial injury and hypoxic myocardial injury . Two (9.1%) of the MICU patients presented with acute ischeamic strokes. In contrast, a study by Merkler et al. reported that 1.6% of patients with COVID-19 visiting the ER department had ischeamic strokes . Both patients had a medical history of hypertension and diabetes.
With increased knowledge of coagulopathies in COVID-19 patients and the associated risks of mortality, most hospital protocols sought to therapeutically anticoagulate COVID-19 patients with severe illness and high d-dimer level although no clear studies have been done to back these measures . Although routine screening for DVTs with doppler scan was not done, none of the MICU patients presented clinically with suspected DVTs but presence of pulmonary embolism could not be ruled out in the absence of CT pulmonary angiograms. Acute severe lower GI bleed however occurred in 2 patients (9.1%), one of whom had a history of diverticular disease. Both patients had therapeutic anticoagulation doses which could have contributed to the acute lower GI bleed with significant hemodynamic compromise.
Laboratory parameters and outcomes: the MICU patients generally had normal median values of Hb, platelets, WBCs and differential cell counts. Lymphopenia is known to occur quite frequently among patients with COVID-19 disease particularly those with severe disease and strongly correlates with mortality [11,12]. However, only 5 (22.7%) of the MICU patients had lymphopenia with no statistically significant effect on patient outcomes. Systemic markers of the heightened immune response are numerous and include procalcitonin, CRP, serum ferritin, ESR and IL-6 . With the exception of procalcitonin levels and IL-6 levels which were not readily available in our setting, the MICU patients had elevated median values of inflammatory markers consistent with their disease severity. The elevated inflammatory markers however, did not significantly affect disease outcome with the exception of serum ferritin which showed a tendency towards poor patient outcome (p=0.06). Abnormal cytokine release and direct viral attachment to ACE2 receptors on the vascular endothelium leads to excess release of coagulation factors promoting thrombotic complications in patients with COVID-19 . Similarly, we found increased levels of D-dimer in a significant number of our patients 19/22 (86.4%) with no clinical evidence of DVT. Also, the median value of troponin T, a marker of cardiac injury was also elevated. However, none of these serum markers significantly impacted mortality in our patients, although the small study population could be a limitation.
Outcomes and associated factors: at the time of study, mortality rate at MICU was 22.7% with 16 (73%) of the patients successfully discharged from the MICU with the exception of one patient who was stable on minimal FiO2 awaiting discharge. Our overall ICU mortality rate was lower compared to 30.9% and 52.5% mortality reported by some studies [10,11]. Although about 45% of the MICU patients developed ARDS similar to 41.8% in a study by Wu et al. we reported 20% mortality among the ARDS patients compared to 52% in the later study. In a US study by Arentz et al. , a higher proportion of the COVID-19 cases (71%) developed ARDS with a mortality of 67%. In both studies all patients with ARDS required invasive ventilation known to be associated with a mortality of >50% . As per local protocol to manage the limited ventilators available, 7 out the 10 MICU patients with ARDS were initially managed on non-invasive ventilation (NIV), with one escalated to invasive ventilation while the other three were on 15L oxygen via non-rebreather mask. The very minimal MV requirement among our cases could also have contributed to the lower mortality rate (20%) in those with ARDS, including the mechanically ventilated patient. Current observational studies have shown better outcomes in COVID-19 patients with hypoxemic respiratory failure who were initiated on non-invasive ventilation compared to those who had invasive ventilation and prevented escalation to invasive ventilation .
Although not statistically significant admitting FiO2 requirements and S/F ratio showed a tendency to affect mortality (p=0.06; p=0.07). The notable difference in the FiO2 requirements and S/F ratio between survivors and non-survivors, similarly, observed in a study by Yang et al. indicates that these parameters reliably depicts disease severity and predicts poor outcome . Earlier on in the pandemic, the use of systemic corticosteroids was not recommended, however, some studies had shown mortality benefits of steroid use in COVID-19 associated ARDS, but the dose and duration of therapy was unclear [29,30]. As per the MICU protocol, IV methylprednisolone was added to the treatment protocol as an immune modulator using S/F ratio and CRP levels to categorize patients at risk of deterioration. It was observed in the current review that the duration of therapy with methylprednisolone was significantly shorter in the non-surviving MICU patients (p=0.04). This is likely a reflection of late patient transfer to the ICU as well as late initiation of immune-modulatory therapy such as methylprednisolone, which has been shown to mitigate the cytokine storm and its associated multi-organ dysfunction thereby reducing mortality among severe to critically COVID-19 patients [29,30].
The possible reasons for the comparatively shorter patient stay at MICU (4.1 ± 3.0) could be due to the fact that the unit had only one mechanically ventilated patient compared to other studies [10,11,20]. From the study results as shown in Figure 2, those on therapeutic dose of enoxaparin appeared to have had a shorter ICU stay compared to those on prophylactic doses, though this was not statistically significant and its use did not affect patient outcomes. Although other organ dysfunction in COVID-19 particularly the involvement of the cardiovascular system contributes significantly to mortality, our results showed no significant association between the presence of organ dysfunction and disease outcome.
The early use of systemic corticosteroid therapy among MICU patients may have contributed to the relatively lower mortality rate and shorter ICU stay observed at the unit in the early months of the pandemic. We suggest the use of S/F ratio in low resource settings for early identification of COVID-19 patients at risk of severe hypoxic failure .
What is known about this topic
- Patients admitted to ICU with severe/critical COVID-19 have a high mortality;
- Mortality resulting COVID-19 is highly age dependent and variations in population age, or in the age of admitted patients may have a significant influence on mortality rate.
What this study adds
- Emphasizes the benefits of the recently recommended use of systemic corticosteroids in severe/critically ill COVID-19 patients;
- Therapeutic doses of anticoagulants administration may decrease length of ICU stay in severe/critical COVID-19 patients;
- Median SpO2/FiO2 level was significantly higher in persons with only COVID-19 pneumonia compared to those with ARDS (p<0.001) and use of ratio should be encouraged in resource limited countries.
The authors declare no competing interests.
Conception of the study: PA and JAM; records review and data extraction: VG, JAM, SB, DT, EK and PA; statistical analysis: VG and ETA; writing of the first draft of the manuscript: PA, JAM and ETA; review and editing: all authors; supervision of the whole study: PA. All the authors have read and agreed to the final manuscript.
We acknowledge all study participants and staff of the medical ICU, KBTH.
Tables and figures
Table 1: demographic and clinical characteristics of patients with COVID-19 infection admitted to the medical intensive care unit at the Korle-Bu Teaching Hospital, April - June 2020
Table 2: comorbidities among patients with COVID-19 infection admitted to the medical intensive care unit of the Korle-Bu Teaching Hospital, April - June 2020
Table 3: complications among patients with COVID-19 infection admitted to the medical intensive care unit of the Korle-Bu Teaching Hospital, April - June 2020
Table 4: laboratory characteristics of patients with COVID-19 infection admitted to the medical intensive care unit at the Korle-Bu Teaching Hospital, April - June 2020
Table 5: treatment administered to patients with COVID-19 infection admitted to the medical intensive care unit of the Korle-Bu Teaching Hospital, April - June 2020
Table 6: association between clinical outcomes and demographic, clinical and laboratory characteristics of patients with COVID-19 infection admitted to the medical intensive care unit at the Korle-Bu Teaching Hospital, April - June 2020
Figure 1: box plot showing the distribution of SP02/FI02 ratio by type of respiratory complication
Figure 2: box plot showing the distribution of duration in ICU by type of anticoagulation received during ICU admission
- Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ. 2020 Aug 15;730:138996. PubMed | Google Scholar
- Dzinamarira T, Dzobo M, Chitungo I. COVID-19: a perspective on Africa's capacity and response. J Med Virol. 2020;92(11):2465-2472. PubMed | Google Scholar
- Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238-e244. PubMed | Google Scholar
- World Health Organization. Coronavirus disease (COVID-19): situation report, 174. Geneva World Health Organization. 2020.
- Guan W, Ni Z, Hu Y, Liang W, Ou C, He J et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. PubMed | Google Scholar
- Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM et al. Epidemiology, clinical course and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-1770. PubMed | Google Scholar
- World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. Google Scholar
- Zheng KI, Feng G, Liu WY, Targher G, Byrne CD, Zheng MH. Extrapulmonary complications of COVID-19: a multisystem disease. J Med Virol. 2020 Jul 10:10.1002/jmv.26294. PubMed | Google Scholar
- Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 201 Crit Care Med. 2020;48(9):1358-1364. PubMed | Google Scholar
- Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020;48(9):e799-e804. PubMed | Google Scholar
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. PubMed | Google Scholar
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481. PubMed | Google Scholar
- ICNARC. ICNARC report on COVID-19 in critical care: participation and population coverage: critical care unit participation. 2020.
- Bashar FR, Vahedian-Azimi A, Farzanegan B, Goharani R, Shojaei S, Hatamian S et al. Comparison of non-invasive to invasive oxygenation ratios for diagnosing acute respiratory distress syndrome following coronary artery bypass graft surgery: a prospective derivation-validation cohort study. J Cardiothorac Surg. 2018;13(1):123. PubMed | Google Scholar
- Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic teriew and meta-analysis of observational studies. Anaesthesia. 2020;75(10):1340-49. PubMed | Google Scholar
- Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossow J, da Silva J et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 - Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545-550. PubMed | Google Scholar
- Mahase E. COVID-19: why are age and obesity risk factors for serious disease. BMJ. 2020;371:m4130. PubMed | Google Scholar
- Bwire GM. Coronavirus: why men are more vulnerable to COVID-19 than women. SN Compr Clin Med. 2020;1-3. PubMed | Google Scholar
- Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32. PubMed | Google Scholar
- Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-1614. PubMed | Google Scholar
- Cui X, Yu X, Wu X, Huang L, Tian Y, Huang X et al. Acute kidney injury in patients with the coronavirus disease 2019: a multicenter study. Kidney Blood Press Res. 2020;45(4):612-622. PubMed | Google Scholar
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. PubMed | Google Scholar
- Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690. PubMed | Google Scholar
- Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268-2270. PubMed | Google Scholar
- Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810. PubMed | Google Scholar
- Pan S, Zhang H, Li C, Wang C. Cardiac arrest in severe acute respiratory syndrome: analysis of 15 cases. Zhonghua Jie He He Hu Xi Za Zhi. 2003;26(10):602-605. PubMed | Google Scholar
- Merkler AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol. 2020;77(11):1-7. PubMed
- Sivaloganathan AA, Nasim-Mohi M, Brown MM, Abdul N, Jackson A, Fletcher SV et al. Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre. Br J Anaesth. 2020;125(4):e368-e371. PubMed | Google Scholar
- Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5(1):18. PubMed | Google Scholar
- RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020 Jul 17:NEJMoa2021436. PubMed | Google Scholar